文献速递免疫规划卫生政策与健康促进

美国黄热病疫苗使用与嗜神经及嗜内脏疾病风险的回顾性队列研究:基于三个医疗保健数据库

Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
PubMed 文献 · Vaccine · 2022-01-05

本研究利用Optum EHR(2007-2019)、Optum CDM(2004-2019)和IBM MarketScan(2007-2019)三个数据库的脱敏患者信息开展回顾性队列研究,描述美国平民黄热病疫苗接种者特征及免疫抑制性疾病患病情况,并估算接种后30天内嗜神经和嗜内脏疾病的发生比例。共识别92,205例(Optum EHR)、46,539例(Optum CDM)和125,235例(IBM MarketScan)接种者,多数年龄<60岁(18-29岁占比最高),女性比例较高,<1%接种者存在免疫抑制相关疾病;发现4例非致死性嗜神经疾病、0例嗜内脏疾病。

要点

  • 美国三个数据库共识别大量黄热病疫苗接种者,多数年龄<60岁且女性比例较高。
  • 接种者中<1%存在免疫抑制相关基础疾病。
  • 接种后30天内嗜神经疾病发生比例在Optum EHR为每10万接种者1.41(95%CI 0.15-6.61),IBM MarketScan为3.04(95%CI 0.86-8.11),Optum CDM无事件。

核心结论

  • 本研究提供了美国平民黄热病疫苗使用的最新见解,并支持黄热病疫苗在美国实践中的安全性。
  • 接种者中免疫抑制相关基础疾病患病率低,提示医疗从业者对疫苗接种指南的良好依从性。
  • 接种后发生嗜神经和嗜内脏疾病的风险仍然罕见。

研究设计与样本

  • 回顾性队列研究,使用Optum电子健康记录(EHR)(2007-2019)、Optum Clinformatics Data Mart(CDM)(2004-2019)和IBM MarketScan(2007-2019)数据库的脱敏患者信息。
  • 通过相关疫苗接种和操作代码识别黄热病疫苗受种者,描述人口学特征和基础疾病,计算接种后30天内嗜神经和嗜内脏疾病的发生比例及95%CI,并依据当前YEL-AND和YEL-AVD临床指南排除不可能病例。

主要发现

  • Optum EHR、Optum CDM和IBM MarketScan数据库分别检索到92,205例、46,539例和125,235例黄热病疫苗受种者。
  • 大多数受种者年龄<60岁(18-29岁比例最高),总体女性比例较高。
  • 少数受种者(<1%)存在导致免疫抑制的疾病。
  • 发现4例非致死性嗜神经疾病病例和0例嗜内脏疾病病例。
  • 接种后嗜神经疾病发生比例在Optum EHR为每10万受种者1.41(95%CI 0.15-6.61),在IBM MarketScan为每10万受种者3.04(95%CI 0.86-8.11),Optum CDM未发现事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yellow fever (YF) vaccines are highly effective and have a well-established safety profile despite the risk of rare serious adverse events (SAEs), vaccine-associated neurotropic (YEL-AND) and viscerotropic disease (YEL-AVD). This study aimed to describe US civilian YF vaccine usage, the population characteristics and pre-existing immunosuppressive medical conditions among those vaccinated, and to provide updated risk estimates of neurotropic and viscerotropic disease post-vaccination. METHODS: A retrospective cohort study was conducted using de-identified patient information from Optum Electronic Healthcare Record (EHR) (2007-2019), Optum Clinformatics Data Mart (CDM) (2004-2019) and IBM MarketScan (2007-2019) databases. YF vaccine recipients were identified using relevant vaccination and procedural codes. Demographic characteristics and pre-existing medical conditions were described. Incidence proportions with 95% confidence intervals (CI) of neurotropic and viscerotropic diseases occurring ≤ 30 days post-vaccination, after exclusion of unlikely cases based on current clinical guidelines of YEL-AND and YEL-AVD, were calculated. RESULTS: A total of 92,205, 46,539 and 125,235 YF vaccine recipients were retrieved from Optum EHR, Optum CDM and IBM MarketScan databases, respectively. The majority of vaccine recipients were aged < 60 years (highest proportion aged 18-29 years) with a higher proportion of females overall. Few vaccine recipients (<1%) had conditions predisposing them to immunosuppression. Four non-fatal cases of neurotropic disease and zero cases of viscerotropic disease were identified. The incidence proportion of post-vaccination neurotropic disease was 1.41 (95% CI: 0.15-6.61) and 3.04 (95% CI: 0.86-8.11) per 100,000 vaccine recipients in Optum EHR and IBM MarketScan, respectively, with no events identified in Optum CDM. CONCLUSIONS: This study provides updated insights into current YF vaccine usage in US civilian recipients and supports the safety profile of YF vaccines in US practice. The low frequency of pre-existing immunosuppressive medical conditions among vaccine recipients suggests good adherence to vaccination guidelines by healthcare practitioners. The risk of developing neurotropic and viscerotropic disease post-vaccination remains rare.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ledlie S, Ricci C, Pan C, et al. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases. Vaccine. 2022. PMID: 34996642. doi:10.1016/j.vaccine.2021.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。